DDInter255 DDInter1376
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
Busulfan {u} (Compound) binds {v} (Gene) MGST2
Busulfan {u} (Compound) upregulates {v} (Gene) DUSP11
Busulfan {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Busulfan {u} (Compound) downregulates {v} (Gene) MRPL19
Busulfan {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Busulfan (Compound) treats hematologic cancer (Disease)
Busulfan (Compound) binds MGST2 (Gene)
Busulfan (Compound) upregulates DUSP11 (Gene)
Busulfan (Compound) is included by Alkylating Activity (Pharmacologic Class)
Busulfan (Compound) downregulates MRPL19 (Gene)
Busulfan (Compound) causes Dermatitis bullous (Side Effect)